Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met-overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

Camidge, D. RossBar, JairHorinouchi, HidehitoGoldman, Jonathan W.Moiseenko, Fedor VladimirovichFilippova, ElenaCicin, Irfan2024-06-122024-06-1220220732-183X1527-7755https://hdl.handle.net/20.500.14551/26813Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2022 -- ELECTR NETWORK[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met-overexpressing (OE) advanced non-small cell lung cancer (NSCLC).Conference Object4016Q1WOS:000863680302206